Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT01165996
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure
- Conditions
- Interventions
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2010-09-03
- Lead Sponsor
- King's College London
- Target Recruit Count
- 50
- Registration Number
- NCT01133886
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01130506
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 41
- Registration Number
- NCT01098084
- Locations
- 🇫🇷
CH Angers, Angers, France
🇫🇷Hôpital Avicenne, Bobigny, France
🇫🇷CHU de Bicêtre, Le Kremlin-Bicêtre, Ile de France, France
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
- Conditions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Registration Number
- NCT01026376
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01011283
- Locations
- 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 19
- Registration Number
- NCT01001143
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
- Conditions
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00986804
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT00968071
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00941109
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.